BCAX - Bicara Therapeutics Inc. Common Stock
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$28.60
DETAILS
HIGH:
$42.00
LOW:
$18.00
MEDIAN:
$28.00
CONSENSUS:
$28.60
UPSIDE:
31.92%
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Operating Expenses | ||||
| R&D Expenses | 125.1 | 63.6 | 30.6 | 31.3 |
| SG&A Expenses | 30.5 | 18.8 | 9.3 | 6.3 |
| Other Expenses | 0 | 0 | 0 | 0 |
| Operating Expenses | 155.6 | 82.4 | 39.9 | 37.7 |
| Operating Income | ||||
| Operating Income | (155.6) | (82.4) | (39.9) | (37.7) |
| Interest Expense | 0 | 0 | 0 | 0.1 |
| Interest Income | 17.9 | 14.6 | 1.3 | 0.0 |
| Profitability | ||||
| EBITDA | (155.6) | (82.3) | (39.9) | (37.7) |
| EBIT | (155.6) | (82.4) | (39.9) | (37.7) |
| Income Before Tax | (137.7) | (67.8) | (52.0) | (37.8) |
| Income Tax Expense | 0.2 | 0.2 | 0.0 | 0.0 |
| Net Income | (137.9) | (68.0) | (52.0) | (37.8) |
| Per Share Data | ||||
| EPS (Basic) | -2.52 | -1.25 | -1.00 | -0.73 |
| EPS (Diluted) | -2.52 | -1.25 | -1.00 | -0.73 |
| Shares Outstanding | 54.7 | 54.4 | 51.8 | 51.8 |
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Current Assets | ||||
| Cash & Cash Equivalents | 96.7 | 489.7 | 230.4 | 4.2 |
| Short-Term Investments | 318.1 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Other Current Assets | 7.3 | 12.8 | 0.1 | 0.1 |
| Total Current Assets | 422.1 | 502.5 | 231.1 | 5.0 |
| Non-Current Assets | ||||
| Property, Plant & Equipment | 2.0 | 0.8 | 0.8 | 0.6 |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 6.9 | 6.6 | 2.1 | 1.1 |
| Total Non-Current Assets | 8.9 | 66.7 | 2.9 | 1.7 |
| Total Assets | 431.0 | 569.2 | 234.0 | 6.7 |
| Current Liabilities | ||||
| Account Payables | 5.5 | 4.5 | 3.2 | 5.1 |
| Short-Term Debt | 1.1 | 0.6 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 22.3 | 9.8 | 0 | 0 |
| Total Current Liabilities | 28.9 | 18.0 | 15.1 | 23.9 |
| Non-Current Liabilities | ||||
| Long-Term Debt | 0.6 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 59.2 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0.0 | 0.1 |
| Total Non-Current Liabilities | 0.6 | 59.3 | 0.4 | 0.1 |
| Total Liabilities | 29.5 | 77.3 | 15.5 | 24.0 |
| Stockholders' Equity | ||||
| Common Stock | 0 | 0.0 | 0.0 | 0.0 |
| Retained Earnings | 0 | (221.0) | (153.0) | (101.0) |
| Accumulated Other Comprehensive Income | 0 | 0 | 0 | 0 |
| Total Stockholders' Equity | 401.5 | 491.9 | 218.5 | (17.3) |
| Total Liabilities & Equity | 431.0 | 569.2 | 234.0 | 6.7 |
| Debt Metrics | ||||
| Total Debt | 1.7 | 0.7 | 0.7 | 0 |
| Net Debt | (95.0) | (489.0) | (229.8) | (4.2) |
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | (137.9) | (68.0) | (52.0) | (37.8) |
| Depreciation & Amortization | 0.4 | 0.1 | 0.0 | 0.0 |
| Stock-Based Compensation | 15.0 | 7.4 | 1.9 | 0.8 |
| Change in Working Capital | 14.8 | (14.1) | (9.6) | 4.9 |
| Other Non-Cash Items | 0.9 | (0.1) | 14.1 | 0 |
| Operating Cash Flow | (106.8) | (74.8) | (45.6) | (32.1) |
| Investing Activities | ||||
| Capital Expenditure | (0.3) | (0.1) | (0.6) | (0.2) |
| Acquisitions | 0 | 0 | 0 | 0 |
| Purchases of Investments | (318.2) | 0 | 0 | 0 |
| Sales/Maturities of Investments | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0.1 | 0 | 0 |
| Investing Cash Flow | (318.5) | (0.0) | (0.6) | (0.2) |
| Financing Activities | ||||
| Net Debt Issuance | 0 | 0 | 0 | 0 |
| Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 1.6 | 0.1 | 0.2 |
| Financing Cash Flow | 32.3 | 334.0 | 272.5 | 31.7 |
| Cash Position | ||||
| Net Change in Cash | (393.0) | 259.3 | 226.3 | (0.6) |
| Cash at Beginning | 489.7 | 230.4 | 4.2 | 4.7 |
| Cash at End | 96.7 | 489.7 | 230.4 | 4.2 |
| Free Cash Flow | (107.1) | (74.8) | (46.2) | (32.3) |
| Key Metrics | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Operating Income | (155.6) | (82.4) | (39.9) | (37.7) |
| Net Income | (137.9) | (68.0) | (52.0) | (37.8) |
| EPS (Diluted) | -2.52 | -1.25 | -1.00 | -0.73 |
| Balance Sheet | ||||
| Cash & Equivalents | 96.7 | 489.7 | 230.4 | 4.2 |
| Total Assets | 431.0 | 569.2 | 234.0 | 6.7 |
| Total Debt | 1.7 | 0.7 | 0.7 | 0 |
| Stockholders' Equity | 401.5 | 491.9 | 218.5 | (17.3) |
| Cash Flow | ||||
| Operating Cash Flow | (106.8) | (74.8) | (45.6) | (32.1) |
| Capital Expenditure | (0.3) | (0.1) | (0.6) | (0.2) |
| Free Cash Flow | (107.1) | (74.8) | (46.2) | (32.3) |